BMS woes continue

  1. RBx
    643 Posts.
    lightbulb Created with Sketch. 1002
    Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market - The ASCO Post

    Opdivo was granted accelerated approval in 2018 for small cell lung cancer based on surrogate endpoints, but has now been withdrawn from the US market, having failed to achieve its primary endpoint of Overall Survival in confirmatory studies.

    This emphasises the urgent need that BMS and Merck have to find ways to make Opdivo and Keytruda work in more patients and in more forms of cancer.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
9.8¢
Change
0.000(0.00%)
Mkt cap ! $28.63M
Open High Low Value Volume
9.7¢ 9.8¢ 9.5¢ $15.43K 159.9K

Buyers (Bids)

No. Vol. Price($)
1 47773 9.3¢
 

Sellers (Offers)

Price($) Vol. No.
9.8¢ 47899 1
View Market Depth
Last trade - 16.10pm 12/09/2025 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.